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Diabetic peripheral neuropathy (DPN) is a frequent complication of type 2 diabetes mellitus (DM) and may involve small and
large peripheral nerve fibers. Recent evidence suggests a role of cytokines in DPN. The paper is aimed at exploring whether the
serum concentration of cytokines is associated with small and large nerve fiber function and with neuropathic pain (NP). We
recruited a group of 32 type 2 DM patients who underwent serum cytokines (TNF-𝛼, IL-2, IL-4, IL-6, and IL-10) dosage as well as
electrodiagnostic and quantitative sensory testing (QST) assessment to explore damage to large and small nerve fibers. Raised serum
levels of IL-6 and IL-10 correlated with markers of large nerve fiber sensory and motor axonal damage. Raised IL-10 serum level
was associated with signs of motor nerve demyelination. No differences were found in pain characteristics and electrodiagnostic
and QST markers of small nerve fiber function in relation to cytokines serum levels. IL-6 and IL-10 serum levels were associated
with large nerve fiber damage but not to small fibers function or NP. IL-6 and IL-10 cytokines might play a role in the pathogenesis
of nerve fiber damage or represent a compensatory or neuroprotective mechanism.
1. Introduction
Diabetic peripheral neuropathy (DPN) is the most common
long-term complication of type 2 diabetes mellitus (DM)
and affects approximately half of the patients over the
course of disease [1]. Small and large peripheral nerve fibers
may be involved in DPN. Large nerve fiber damage causes
paresthesia, sensory loss, and muscle weakness and small
nerve fiber damage is associated with pain, anesthesia, foot
ulcer, and autonomic symptoms. In clinical practice, the
diagnosis of DPN is made on the base of questionnaires
and clinical evaluation and electrodiagnostic studies are
considered to be rarely helpful [1]. Nerve conduction study
(NCS) however is important in experimental studies in that
itmay document the extent and severity of nerve involvement
and demonstrates the presence of axonal damage and/or
demyelination.
The mechanisms of DPN are only partially understood,
and hyperglycemia, dyslipidemia, and insulin resistance are
considered to be involved in its pathophysiology. The obser-
vation that successful treatment of hyperglycemia often fails
to prevent DPN suggests the presence of early biochemical
mediators that, once activated, may act independently of the
initial stimulus. The biochemical pathways leading to nerve
damage in DPN are complex and they include the accumu-
lation of sorbitol, lipoxygenase activation, oxidization, and
glycation of proteins and lipoproteins. Glucose and oxidized
and glycated proteins may bind various receptors on neurons
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and endothelial cells and activate inflammatory signaling
mechanisms and disrupt mitochondrial metabolism leading
to oxidative stress and DPN [2].
Chronic hypoxia secondary to microvessel involvement
and accumulation of advanced glycation end products [2, 3]
may contribute to the induction of a low-grade chronic, sub-
clinical inflammation in patients with DPN [4, 5]. Emerging
evidence indicates that cytokines including tumor necrosis
factor alpha (TNF-𝛼), interleukins (ILs), adhesionmolecules,
chemokines, and other soluble molecules may be involved
in the pathogenesis of experimental diabetic neuropathy [2].
Cytokines have been documented to contribute to an array of
peripheral neuropathies, including immune-mediated neu-
ropathies and chemotherapy-induced peripheral neuropathy
[6].
Neuropathic pain (NP) is a common complication of
DPN and is associated with peripheral and central mecha-
nisms of sensitization [1, 7]. Cytokines have been found to
contribute to the pathogenesis of NP in animal models [8]
and in humans [9].
The main limitations of animal models of DPN and NP
[10] are that they do not clearly separate DPN from NP
and that they mainly explore evoked pain, whereas patients
often complain of spontaneous NP [11, 12]. There are few
reports on the role of cytokines in patients with DM, where
the diagnosis of DPN was usually made on the basis of
questionnaires and/or clinical evaluation [4, 13–15], but they
leave some open questions, because neurophysiological or
psychophysical data on the type and amount of peripheral
nerve damage, as well as hints about possible mechanisms of
nerve damage, are scarce.
To add a piece of information on this topic, the present
study is aimed at exploring the possible role of cytokines as
markers of peripheral nerve damage in DPN. To this goal,
electrodiagnostic and quantitative sensory testing (QST)
measures of loss-of-function of large and small nerve fibers
were recorded in a group of patients with type 2 DM. NCS
explores the function of large (A-beta) nerve fibers, while
sympathetic skin response (SSR) documents the damage of
small (myelinated A-delta and unmyelinated C) nerve fibers
[16]. Reduced amplitude of sensory andmotor potential indi-
cates axonal damage and reduction of conduction velocity is
associated with demyelination. F-wave latency measures the
conduction across the whole nerve and is sensitive to changes
at the proximal nerve site [17]. QST explores the presence
of gain- and loss-of-function signs of different nerve fibers
[18]. AmongQSTmeasures, we focused on thermal detection
thresholds, which document damage to small nerve fibers.
We correlated signs of damage to different nerve fibers to the
presence and serum concentration of cytokines. We included
type 2 DM patients regardless of the presence/absence of
DPN because we were interested in the correlation between
cytokine levels andnerve fiber function across different stages
of DPN, including preclinical ones.
2. Materials and Methods
2.1. Subjects. We recruited 32 subjects (17 men, mean age
63.6 ± 9.3 years, range 47–79) who were affected with type
2 DM according to American Diabetes Association criteria
[19] and fulfilled the following inclusion/exclusion criteria:
age ≥ 18 years, no cognitive impairment (Mini Mental
State Evaluation score ≥ 25/30), no coexistent neurological
disease except for DPN, no severe systemic, infectious or
autoimmune diseases, organ failure, hematological diseases
or malignancies, no use of analgesic or anti-inflammatory
drugs, corticosteroids, or immune modulating therapies.The
study was carried out in accordance with the principles of
the Declaration of Helsinki as revised in 2001 and approved
by local ethics committee. All patients gave signed informed
consent prior to inclusion in the study.
2.2. Clinical and Metabolic Variables. In all patients body
mass index (BMI), waist circumference (WC), therapy for
DM (oral hypoglycemic agents, insulin, combined treatment)
andmeasured blood pressure, serum fasting glucose, glycated
hemoglobin (HbA1c), creatinine, cholesterol, and triglyceride
level, and urinary albumin excretion (UAE) were recorded.
Hypertension was defined according to the 2013 European
Society of Hypertension and the European Society of Cardi-
ology criteria [20]. Hypercholesterolemia was defined as total
serum cholesterol≥ 5.18mmol/L and hypertriglyceridemia as
total serum triglyceride ≥ 1.7mmol/L [21].
All the patients were asked on the presence of pain in the
preceding month and pain intensity was measured on a 0–
10 numerical rating scale (NRS). The presence of probable
or definite NP was diagnosed according to the NP grading
system [22].
2.3. Electrodiagnostic Assessment. The electrodiagnostic as-
sessment was done with a four-channel Oxford Synergy elec-
tromyograph (Medelec Oxford, UK). An infrared lamp was
used to maintain skin temperature > 31∘C during all the tests.
All the patients underwent sensory and motor NCS (band-
pass filter 10–5000Hz) of the lower limb nerves according
to the American Association of Electrodiagnostic Medicine
guideline [23] to explore the function of large nerve fibers.
Amplitude of sensory nerve action potential (SNAP) and
sensory nerve conduction velocity (SNCV) of the left sural
nerve, and amplitude of compound muscle action potential
(CMAP), motor nerve conduction velocity (MNCV), and
minimal F-wave latency of the left peroneal nerve were
recorded. SSR to supramaximal median nerve electrical
stimulation was recorded (band-pass filter 0.1–100Hz) from
the left foot in all the patients.
2.4. Quantitative Sensory Testing. QST was performed by
a trained examiner (F.M.) using a TSA-II NeuroSensory
Analyzer (Medoc Ltd., Ramat Yishai, Israel).Thresholds were
determined with the Method of Limits [24, 25]. Heat and
cold stimuli were delivered through a 30 × 30mm2 thermode
attached to the skin of the dorsal surface of the left foot
with a constant pressure. To determine the warm detection
threshold (WDT) and the cold detection threshold (CDT),
the skin was allowed to adapt to a temperature of 32∘C
for 5min and then cooled down or warmed up linearly
at a slow rate (1∘C/s) until warm and cold sensation was
perceived, at which moment the subject stopped the stimulus
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Table 1: Clinical characteristics of the patients.
IL-6+ (n = 14) IL-6− (n = 18) IL-10+ (n = 5) IL-10− (n = 27)
Age (years) 65.9 ± 9.2 62.4 ± 8.8 68.4 ± 9.4 63.1 ± 8.9
Sex (M/F) 8/6 9/9 4/1 13/14
Disease duration (years) 14.8 ± 8.3 15.2 ± 11.5 18.4 ± 9.5 14.4 ± 10.2
Therapy (oral/insulin/combined) 7/6/1 10/6/2 2/3/0 15/9/3
BMI (kg/m2) 30.2 ± 6.9 29.3 ± 4.3 25.2 ± 3.2* 30.5 ± 5.5
WC (cm) 108.4 ± 16.2 100.6 ± 10.5 97.6 ± 7.2 105.2 ± 14.3
Hypertension (yes/no) 9/5 11/7 4/1 18/9
Hypercholesterolemia (yes/no) 6/8 9/9 0/5 15/12
Hypertriglyceridemia (yes/no) 3/11 7/11 0/5 10/17
Pain (yes/no) 12/2 14/4 4/1 22/5
Pain severity (0–10NRS) 2.1 ± 2.3 2.5 ± 2.3 1.9 ± 1.2 2.4 ± 2.4
Serum fasting glucose (mmol/L) 9.0 ± 2.7 9.0 ± 2.8 8.4 ± 2.6 9.3 ± 2.7
HbA1c (mmol/mol) 63 ± 14* 54 ± 12 56 ± 8 58 ± 16
Creatinine (𝜇mol/L) 97.2 ± 53.0 97.4 ± 61.9 106.1 ± 79.6 97.2 ± 53.0
UAE (mg/L) 288 ± 193 210 ± 204 253 ± 235 314 ± 255
BMI: body mass index, WC: waist circumference, NRS: numerical rating scale; HbA1c: glycated hemoglobin, and UAE: urinary albumin excretion from spot
urine sample. *p < 0.05.
by pressing a button on a patient response unit. Warm
and cold stimulation were repeated four times each and
the mean of peak temperatures was considered threshold.
Testing was preceded by detailed instructions to subjects and
a demonstration test for each type of stimulus and performed
in a designated, quiet room with no distractions [18, 26].
QST evaluation explored the function of small nerve fibers.
In particular, WDT and CDT measure C and A-delta nerve
fiber loss-of-function, respectively [27].
2.5. Blood Collection and Cytokines Assay. Blood samples
were obtained in the nonfasting state at the same time of
the day (i.e., 2 pm-3 pm) in all the patients. Glucose serum
concentration at the time of blood sample was checked.
After 10min of rest in the supine position, blood samples
were collected from the antecubital vein. Serum and plasma
were immediately separated by centrifugation and stored
in aliquots at −80∘C until analysis. Serum concentration
of TNF-𝛼 (n.v. < 15.6 pg/mL), IL-2 (n.v. < 31.2 pg/mL), IL-
4 (n.v. < 31.2 pg/mL), IL-6 (n.v. < 3.12 pg/mL), and IL-10
(n.v. < 7.8 pg/mL) were assessed in duplicate by an enzyme-
linked immunosorbent assay (ELISA) kit (Quantikine, R&D
Systems,Minneapolis, USA), according to themanufacturer’s
protocol.
2.6. Statistical Analysis. All tests were carried out with the
IBM SPSS version 20.0 statistical package. The normality
of variable distribution was analyzed with the Skewness-
Kurtosis test. Continuous variables were explored with
ANOVA and post hoc 𝑡-test with Bonferroni’s correction.
Homogeneity of variance was analyzed with the Levene
test.The data were transformed (logarithmic transformation)
before submitting them to ANOVA in case of an inequality
in the variances. The nonparametrical Mann-Whitney 𝑈
test was applied in case the distribution was not normal.
Pearson’s 𝜒2 test with Yates’ correction for continuity was
applied to dichotomous variables. The correlation between
the serum concentration of cytokines and electrodiagnostic
parameters and other potential confounders (glucose serum
concentration, age, BMI, sex, diabetes duration, and HbA1c)
was explored with Spearman’s 𝜌 correlation coefficient. The
variables, which turned out to be significant with Spear-
man’s 𝜌 correlation coefficient, were entered intomultivariate
regression analysis.𝑝 < 0.05 (two-tailed) was taken as the
significance threshold for all the tests.
3. Results
Clinical characteristics of the patients are reported in Table 1.
Large fiber neuropathywas found in 7 patients, small fiber
neuropathy in 8, and neuropathy involving both large and
small fibers in 11, while 6 patients had no neuropathy.
TNF-𝛼, IL-2, and IL-4 were within normal values in all
patients. IL-6 was raised in 14 patients (IL-6+ group) and
normal in 18 patients (IL-6− group). IL-10 was raised in 5
patients (IL-10+ group) and reduced in 27 patients (IL-10−
group).
BMI was significantly smaller in IL-10+ patients (25.2 ±
3.2 kg/m2) in comparison to the IL-10− group (30.5 ±
5.5 kg/m2; Mann-Whitney 𝑈 test: 𝑝 = 0.02; Table 1).
HbA1c was significantly higher in the IL-6+ group (63 ±
14mmol/mol) than in the IL-6− one (54 ± 12mmol/mol;
Mann-Whitney 𝑈 test: 𝑝 = 0.03; Table 1). The other
demographic (age, sex), clinical (disease duration, therapy
for DM, BMI, WC, hypertension, hypercholesterolemia, and
hypertriglyceridemia), and metabolic variables (serum fast-
ing glucose, HbA1c, creatinine, and UAE) did not signifi-
cantly differ according to the presence or absence of raised
IL-6 and IL-10 (Table 1).
Pain was reported by 26 patients, and NP was diagnosed
in 18 of them. The number of patients with pain, the number
of patients with NP, and the pain severity according to NRS
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Table 2: Electrodiagnostic measures.
IL-6+ (n = 14) IL-6− (n = 18) 𝑝 IL-10+ (n = 5) IL-10− (n = 27) 𝑝
Sural nerve
SNAP amplitude (𝜇V) 4.4 ± 6.8, 6.6 9.0 ± 6.9, 10.5 0.033 1.6 ± 3.5, 0.8 8.2 ± 7.2, 10.0 0.032
SNCV (m/s) 47.5 ± 9.8, 47.2 45.3 ± 8.5, 43.8 n.s. 49.0 ± 10.9, 47.0 45.8 ± 8.9, 45.3 n.s.
Common peroneal nerve
CMAP amplitude (mV) 3.2 ± 2.2, 5.3 5.8 ± 3.7, 7.4 0.030 1.0 ± 1.3, 0.5 5.4 ± 3.2, 6.5 0.003
MNCV (m/s) 40.0 ± 6.5, 43.9 42.1 ± 7.0, 44.2 n.s 31.8 ± 5.2, 34.0 42.2 ± 6.1, 44.6 0.009
F-wave minimal latency (ms) 54.7 ± 10.5, 52.0 48.5 ± 6.8, 49.2 n.s. 67.4 ± 13.5, 65.2 49.3 ± 6.5, 49.2 0.042
SSR
Latency (s) 1.4 ± 0.3, 1.3 1.5 ± 0.2, 1.4 n.s. 1.5 ± 0.1, 1.6 1.5 ± 0.3, 1.4 n.s.
Amplitude (𝜇V) 0.9 ± 0.6, 0.8 1.0 ± 0.7, 1.0 n.s. 1.0 ± 0.3, 0.9 1.0 ± 0.7, 1.0 n.s.
Data are presented as mean ± SD, median. p values are from Mann-Whitney 𝑈 test. SNAP: sensory nerve action potential, SNCV: sensory nerve conduction
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Figure 1: The correlation between the serum concentration of IL-6 and sural nerve sensory nerve action potential (SNAP) amplitude
(Spearman’s 𝜌 correlation coefficient =−0.085,𝑝 < 0.001; panel (a)) and common peroneal nerve compoundmuscle action potential (CMAP)
amplitude (Spearman’s 𝜌 correlation coefficient = −0.067, 𝑝 = 0.009; panel (b)). For both correlations, Spearman’s 𝜌 correlation coefficient
turned out to be significant.
did not differ in IL-6+ and IL-6− groups or in IL-10+ and IL-
10− groups.
Among electrodiagnosticmeasures, SNAP amplitudewas
significantly smaller in IL-6+ group (4.4 ± 6.8 𝜇V) than in
IL-6− group (9.0 ± 6.9 𝜇V, 𝑝 = 0.033) and in IL-10+ group
(1.6 ± 3.5 𝜇V) than in IL-10− group (8.2 ± 7.2 𝜇V, 𝑝 = 0.032),
CMAP amplitude was significantly smaller in IL-6+ group
(3.2 ± 2.2mV) than in IL-6− group (5.8 ± 3.7mV, 𝑝 = 0.030)
and in IL-10+ group (1.0 ± 1.3mV) than in IL-10− group
(5.4 ± 3.2mV, 𝑝 = 0.003), MNCV was significantly reduced
in IL-10+ group (31.8 ± 5.2m/s) compared to IL-10− group
(42.2 ± 6.1ms, 𝑝 = 0.009), and F-wave minimal latency was
significantly longer in IL-10+ group (67.4 ± 13.5ms) than in
IL-10− group (49.3±6.5ms, 𝑝 = 0.042), while the other NCV
as well as the SSRmeasures did not significantly differ among
groups (Table 2).
Glucose serum concentration at the time of blood sample,
age, BMI, sex, diabetes duration, and HbA1c were not
significantly correlated with IL-6 and IL-10 concentration.
The amplitude of sural nerve SNAP was negatively cor-
related with IL-6 concentration in patients with abnormal
IL-6 values (Spearman’s 𝜌 correlation coefficient = −0.085,
𝑝 < 0.001; Figure 1(a)). The amplitude of common peroneal
CMAP amplitude was negatively correlated with IL-6 con-
centration in patients with increased IL-6 values (Spearman’s
𝜌 correlation coefficient = −0.067, 𝑝 = 0.009; Figure 1(b)).
The correlation between IL-10 concentration and electro-
diagnostic measures was not explored because of the small
number of patients (𝑁 = 5) with increased values of this
cytokine.
QST measures of small nerve fiber damage did not
significantly differ when comparing IL-6+ and IL-6− groups
or IL-10+ and IL-10− groups (Table 3).
Multivariate analysis was not performed because poten-
tial confounders did not turn out to significantly influence
IL-6 or IL-10 concentration.
4. Discussion
The results of our study show that serum cytokines were
abnormally raised in a group of patients with type 2 DM
and that this finding was associated with DPN. Raised serum
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Table 3: Quantitative sensory testing measures.
IL-6+ (n = 14) IL-6− (n = 18) p IL-10+ (n = 5) IL-10− (n = 27) 𝑝
WDT (∘C) 42.8 ± 4.9, 42.9 42.1 ± 4.5, 41.4 n.s. 44.0 ± 5.2, 43.7 42.0 ± 4.4, 41.4 n.s.
CDT (∘C) 20.9 ± 8.9, 25.9 20.7 ± 9.3, 22.7 n.s. 19.7 ± 8.7, 23.8 21.0 ± 9.2, 24.6 n.s.
Data are presented as mean ± SD, median. p values are fromMann-Whitney𝑈 test. WDT: warm detection threshold, CDT: cold detection threshold.
levels of IL-6 and IL-10 correlated with reduced amplitude
of sural nerve SNAP and common peroneal nerve CMAP.
Raised IL-10 serum level was associated with reduced com-
mon peroneal nerve MNCV and delayed minimal F-wave
latency. No differences were found in pain characteristics,
SSR and QST findings in relation to the presence of raised
IL-6 and IL-10. These findings suggest that both cytokines
may be related to axonal damage to large but not small
nerve fibers and that IL-10 may also be associated with nerve
demyelination. These cytokines do not seem to play a direct
role in the pathogenesis of NP in our patients.
The present data add to previous evidence and offer a
new perspective on the role of cytokines and other soluble
immune mediators in the pathogenesis of DPN and help
translating the bulk of data from animalmodels to the clinical
setting in humans.
ILs play different roles in the immune system but they
can be roughly divided into proinflammatory (TNF-𝛼, IL-
4, and IL-6) and anti-inflammatory ones (IL-2, IL-10), and
some of them, which are termed neuropoietic, seem to have
neuroprotective effects [2].
Serum IL-6was raised in 44%of our patients and elevated
IL-6 was significantly and inversely correlated with SNAP
and CMAP amplitude. Taken together these data suggest
a role of IL-6 in peripheral nerve axonal damage. Our
findings are in accordance with a previous report showing
that, among cytokines and inflammation markers, IL-6 was
the most consistently associated with DPN [4, 14]. These
data are also in keeping with the notion that IL-6 is a
proinflammatory cytokine and may affect glial cells and
neurons to set the pathological process of DPN in motion
[2]. IL-6 is also a member of the so-called neuropoietic
cytokine family [28], which reduces neurotoxicity in vitro
and participates in neural development and has neurotrophic
activity in vivo [29]. IL-6was demonstrated to correct periph-
eral nerve dysfunction in experimental diabetes in rats [29]
through correction of vascular endothelium dysfunction and
increase of nerve blood flow via a mechanism that involves
endothelium-derived hyperpolarizing factor [30]. Because of
this contrasting experimental evidence and the absence of a
follow-up in the present study, we cannot say whether IL-6
causes axonal nerve damage or it reflects compensatory or
neuroprotective mechanisms.
Serum IL-10 was raised in 16% of patients and was
associated with reduced SNAP and CMAP amplitude as well
as with reducedMNCV and delayedminimal F-wave latency,
suggesting that this cytokine might be associated with both
axonal degeneration and demyelination. The mechanism of
DPN is considered to be mainly axonal apart from diabetic
patients with chronic inflammatory demyelinating polyneu-
ropathy (CIDP), a condition that is more frequent in diabetic
patients than in the general population. None of our patients
satisfied the diagnostic criteria for CIDP [31], suggesting that
some DPN patients may show demyelinating phenomena
in addition to axonal ones without a clear diagnosis of a
demyelinating polyneuropathy. Alternatively, the severity of
axonal damage involving prevalently higher-velocity nerve
fibers might have resulted in MNCV reduction in our
patients. The number of patients with IL-10 abnormal values
was however small and these results should be interpreted
with caution. Different from MNCV, sural nerve SNCV did
not significantly differ according to IL-10 levels.
IL-10 is considered an anti-inflammatory cytokine.Mino-
cycline, a drug with anti-inflammatory and immunomodu-
latory effects, has been found to cause IL-10 to increase in
parallel with the decrease of proinflammatory cytokines in a
mice model of diabetic neuropathy [32]. We may speculate
that the activation of IL-10 may represent a neuroprotective
mechanism in response to severe peripheral nerve damage.
The view of a compensatory mechanism is in keeping with
previous evidence of raised serum heat shock protein 27,
which has a role in neuroprotection, in patients with DPN
[33], but a larger sample of patients and follow-up data are
necessary to support it.
We could not document any abnormality in TNF-𝛼 in our
patients. This finding was unexpected because this cytokine
has been documented to contribute to the pathogenesis of
type 2 DM complications including DPN [34], NP [8], and
nerve degeneration [35]. However, the role of this cytokine
is still controversial and our results are in accordance with a
previous study, where TNF-𝛼 was not found to be associated
with DPN [4]. Data from animal models documented that
TNF-𝛼was downregulated in the dorsal root ganglion in early
stages of experimental diabetes, while the opposite occurred
in later stages [36]. Itmay thus be hypothesized that one of the
reasons of normal TNF-𝛼 in the present study might be the
inclusion of patients with early or preclinical DPN, given that
19% had no neuropathy and involvement of small and large
fiber was present in only 34% of them.
We could not find any association between pain and
cytokine activation in our population of patients.This finding
is in keeping with the absence of any correlation between
serum cytokines and small nerve fiber damage as docu-
mented by SSRI andQST and with a previous report showing
that thermal detection threshold and painwere not associated
with serum immune mediators [4]. They are, however, in
contrast with previous reports on other types of peripheral
neuropathy, where patients with painful polyneuropathy
show higher levels of serum cytokines in comparison to those
with painless one [9, 15].They also contrast those obtained in
diabetic lumbosacral radiculoplexus neuropathy (DLRPN),
where TNF-𝛼 was found to be elevated and to mirror
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the response to therapy [37]. A number of hypotheses may be
suggested to explain our results. The first is that subclinical
inflammation may only affect certain components of DPN,
whereas others may be independent of immune activation
[4]. The second is that the limited sample of cytokines tested
in the present study did not allow thorough exploration of
immune and inflammatory mechanisms involved in DPN-
related NP [15]. The third is that the relatively low intensity
of pain in our patients, probably resulting from no analgesic
or anti-inflammatory treatment among the inclusion criteria
of the study, might have biased our population towards low
pain severity patients and this might be one of the reasons
of the absence of any correlation with cytokine serum levels.
The fourth one is that, despite the low pain intensity in
our patients, some central sensitization mechanisms might
prevail in the pathogenesis of NP in DPN [1, 7] in contrast
to other types of diabetic neuropathies, such as DLRPN,
where peripheral nerve microvasculitis has been suggested
as the pathogenetic mechanism [37, 38]. Among clinical and
metabolicmeasures, BMIwas significantly smaller in patients
with raised IL-10, and HbA1c was significantly higher in
those with raised IL-6. However, demographic andmetabolic
variables were not significantly correlated with cytokine
serum concentration. These findings together suggest that
the severity of diabetes and metabolic derangement might be
associated with cytokines activation [39], but the absence of
any correlationwith othermetabolic variables impede further
hypotheses.
Limitations of our study include the relatively small
number of patients tested and the examination of serum
levels of cytokines. The level of circulating cytokines might
be influenced by a number of factors that we have tried to
rule out by strict inclusion criteria, but confounding factors
may not be completely ruled out. Exploring the cytokine
level or their expression directly in nervous tissues such as
in small fibers from skin biopsy or in nerve biopsy might
offer data that are more tightly correlated with the clinical
and neurophysiological findings, but these approaches would
have beenmore invasive. Another limitation is that this study
was cross-sectional, so it is not possible to separate risk or
causative factors from merely coincidental associations or
compensatory phenomena. Finally, we did not perform an
extensive evaluation of autonomic functions that represent
another feature of peripheral nerve damage in DM.
5. Conclusions
Exploring NCS and QST data, we have documented that,
among the cytokines we tested, IL-6 and IL-10 were raised in
some patients with DPN and correlated these abnormalities
to axonal and in part demyelinating changes in large nerve
fibers.
The present data might help understanding the patho-
genesis of this complication of type 2 DM and to better
target immune modulating treatments [2] for its prevention
and treatment that to date represent an unsolved issue. The
cross-sectional nature of the study did not allow under-
standing the extent to what these abnormalities contribute to
nerve damage or represent compensatory or neuroprotective
mechanisms. Future studies on larger populations of patients,
with a follow-up, and including data from skin and/or nerve
biopsies and CSF are needed to overcome the limitations of
the present report.
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